MapLight Therapeutics (MPLT) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MapLight Therapeutics (MPLT) has outperformed ARS Pharmaceuticals (SPRY) over the past year, losing 57.5% versus a loss of 61.0%. MapLight Therapeutics is the larger company by market cap ($330.1 million vs $297.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MPLT | SPRY |
|---|---|---|
| Share price | $5.94 | $2.96 |
| Market cap | $330.12M | $297.56M |
| 1-day change | -7.48% | -11.90% |
| YTD return | -66.18% | -74.59% |
| 1-year return | -57.54% | -61.00% |
| 5-year return | — | -58.83% |
| EPS (TTM) | $-6.07 | $-2.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $84.28M |
| Revenue growth (YoY) | — | -5.46% |
| Net income (latest FY) | $-161.15M | $-171.30M |
| Operating margin | — | -212.92% |
| Net margin | — | -203.25% |
| 52-week high | $40.43 | $13.15 |
| 52-week low | $5.93 | $2.44 |
| Distance from 52-week high | -85.31% | -77.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +340.24% | +474.32% |
| Average volume | 458.71K | 1.83M |
| Shares outstanding | 52.85M | 100.53M |
| Employees | 133 | 203 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 203 employees
MPLT vs SPRY FAQ
Which is bigger, MapLight Therapeutics or ARS Pharmaceuticals?
MapLight Therapeutics (MPLT) is larger, with a market capitalization of $330.12M compared with $297.56M for ARS Pharmaceuticals (SPRY).
Which stock has performed better over the past year, MPLT or SPRY?
MPLT returned -57.54% over the past 12 months, compared with -61.00% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are MapLight Therapeutics and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.